CDMO / Avid Bioservices: Production Expansion Capex And High Costs Are Temporary Issues

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2024 Earnings Conference Call September 7, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relation more_horizontal

Avid Bioservices (CDMO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earn more_horizontal

Investors did not warmly greet the latest earnings report from the contract pharmaceutical manufacturer and developer. The company flipped into the re more_horizontal

Avid grew revenue in the quarter and in the year. The company reported falling earnings per share in both the quarter and the year. more_horizontal

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q4 2023 Earnings Conference Call June 21, 2023 4:30 PM ET Company Participants Tim Brons - Investor Relations Ni more_horizontal

Avid Bioservices has recently completed two expansions within its mammalian cell facilities, increasing its manufacturing capacity and potential reven more_horizontal

Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodi more_horizontal

The stock price of Avid Bioservices Inc (NASDAQ: CDMO) increased by 10.85% after hours in the most recent trading session. This is why. more_horizontal